Patents by Inventor Kang-Yell Choi

Kang-Yell Choi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9763994
    Abstract: The present disclosure relates to a composition for promoting wound healing that may be used as a pharmaceutical composition, or a cosmetic composition for promoting wound healing, which contains a polypeptide including an amino acid sequence of SEQ ID NO 1. The composition may be usefully used for a wound care drug or a functional cosmetic product for wound care.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: September 19, 2017
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Kang-Yell Choi, Soung-Hoon Lee, Hyun-Yi Kim
  • Publication number: 20170209451
    Abstract: Disclosed is a composition for inducing the differentiation of neural stem cells into dopaminergic neurons. The composition includes the compound represented by Formula 1 (“AS703026”) as a MEK 1/2 inhibitor. Also disclosed is a method for inducing the differentiation of neural stem cells into dopaminergic neurons by using the composition. Dopaminergic neurons whose differentiation from neural stem cells is induced by the composition and method can be applied to cell replacement therapies and gene therapies for the treatment of neurodegenerative diseases, such as Parkinson's disease, or can be widely used as materials for the examination of drug effects or numerous studies in the development of new drugs.
    Type: Application
    Filed: March 10, 2017
    Publication date: July 27, 2017
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Kang-Yell CHOI, Mi-Yeon KIM, Yeong-Mun KIM
  • Publication number: 20160346329
    Abstract: Disclosed is a composition for inducing the differentiation of neural stem cells into dopaminergic neurons. The composition includes the compound represented by Formula 1 (“AS703026”) as a MEK 1/2 inhibitor. Also disclosed is a method for inducing the differentiation of neural stem cells into dopaminergic neurons by using the composition. Dopaminergic neurons whose differentiation from neural stem cells is induced by the composition and method can be applied to cell replacement therapies and gene therapies for the treatment of neurodegenerative diseases, such as Parkinson's disease, or can be widely used as materials for the examination of drug effects or numerous studies in the development of new drugs.
    Type: Application
    Filed: October 7, 2015
    Publication date: December 1, 2016
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Kang-Yell CHOI, Mi-Yeon Kim, Yeong-Mun Kim
  • Publication number: 20160271104
    Abstract: The present invention provides a composition comprising an indirubin derivative for stimulating longitudinal bone growth. Because the composition for stimulating longitudinal bone growth according to the present invention is shown to be effective in longitudinal bone growth, it may be used not only as a composition for stimulating longitudinal bone growth, but also as a pharmaceutical composition for treating or preventing short stature, microplasia, dwarfism, or precocious puberty.
    Type: Application
    Filed: July 10, 2014
    Publication date: September 22, 2016
    Inventors: Kang-Yell Choi, Hyun Yi Kim, Sehee Choi
  • Publication number: 20160038555
    Abstract: The invention relates to a composition containing extracts of the fruit of Hoveniadulcis Thunb., gallocatechin, and methyl vanillate as active ingredients for preventing and treating bone disease. The extracts of the fruit of Hoveniadulcis Thunb., the gallocatechin, and the methyl vanillate according to the present invention are natural materials and thus cause no side effects, and may activate the Wnt/?-catenin pathway to promote bone formation rather than inhibiting bone decomposition, and therefore may be effective in treating osteoporosis and related diseases. In addition, the extracts of the fruit of Hoveniadulcis Thunb., the gallocatechin, and the methyl vanillate according to the present invention may have the effects regrowing hair and preventing and treating wounds and metabolic diseases related to the activation of Wnt/?-catenin pathway.
    Type: Application
    Filed: March 30, 2012
    Publication date: February 11, 2016
    Inventors: Kang Yell Choi, Pu Hyeon Cha
  • Publication number: 20150309029
    Abstract: Methods of diagnosing cancer and screening for an anti-cancer drug using Ras are provided. Ras has a very significant role as a prevalent proto-oncogene which has abnormalities in most forms of cancer, and thus the methods of diagnosing cancer and screening for an anti-cancer drug using Ras may be applied to various forms of cancer. The generation of various forms of cancer in the early stages may be determined by examining whether or not phosphorylation of Ras occurs at Thr-144 and Thr-148 sites. By such a mechanism, an anti-cancer drug having excellent anti-cancer effectiveness may be screened, or the effectiveness of the anti-cancer drug may be tested.
    Type: Application
    Filed: February 17, 2015
    Publication date: October 29, 2015
    Inventors: Kang-Yell CHOI, Woo-Jeong JEONG
  • Patent number: 9150630
    Abstract: There are provided Idbf (inhibitor of Dvl and bone formation) which is a novel Dvl-binding protein that binds to Dvl to inhibit signal transduction carried out through the Wnt/?-catenin signaling pathway, a gene for coding for the same, the use thereof, and the use of an inhibitor of the Idbf. The Idbf was known to be expressed by activation of the Wnt/?-catenin signaling pathway and bind to Dvl to block signal transduction carried out through the Wnt/?-catenin signaling pathway. Therefore, the Idbf can be used in development of medicines for inhibiting the signal transduction carried out through the Wnt/?-catenin signaling pathway, and an Idbf inhibitor can be used in preparation of medicines for activating the signal transduction carried out through the Wnt/?-catenin signaling pathway.
    Type: Grant
    Filed: August 3, 2009
    Date of Patent: October 6, 2015
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Kang-Yell Choi, Hyun-Yi Kim, Ju-Yong Yoon
  • Publication number: 20150224167
    Abstract: The present disclosure relates to a composition for promoting wound healing that may be used as a pharmaceutical composition, or a cosmetic composition for promoting wound healing, which contains a polypeptide including an amino acid sequence of SEQ ID NO 1. The composition may be usefully used for a wound care drug or a functional cosmetic product for wound care.
    Type: Application
    Filed: December 11, 2014
    Publication date: August 13, 2015
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: KANG-YELL CHOI, SOUNG-HOON LEE, HYUN-YI KIM
  • Patent number: 8952060
    Abstract: Provided is a composition for preventing hair loss or promoting hair growth including valproic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The composition may be applied to various industrial fields, including pharmaceutical, cosmetic and beauty aid industries.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: February 10, 2015
    Assignee: Amorepacific Corporation
    Inventors: Hyoung-Jun Kim, Won Seok Park, Hyun Ju Koh, Pil Joon Park, Su Na Kim, Kang-Yell Choi, Ju-Yong Yoon, Soung-Hoon Lee
  • Publication number: 20120065262
    Abstract: Provided is a composition for preventing hair loss or promoting hair growth including valproic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The composition may be applied to various industrial fields, including pharmaceutical, cosmetic and beauty aid industries.
    Type: Application
    Filed: May 11, 2010
    Publication date: March 15, 2012
    Inventors: Hyoung-Jun Kim, Won Seok Park, Hyun Ju Koh, Pil Joon Park, Su Na Kim, Kang-Yell Choi, Ju-Yong Yoon, Soung-Hoon Lee
  • Publication number: 20110189693
    Abstract: Methods of diagnosing cancer and screening for an anti-cancer drug using Ras are provided. Ras has a very significant role as a prevalent proto-oncogene which has abnormalities in most forms of cancer, and thus the methods of diagnosing cancer and screening for an anti-cancer drug using Ras may be applied to various forms of cancer. The generation of various forms of cancer in the early stages may be determined by examining whether or not phosphorylation of Ras occurs at Thr-144 and Thr-148 sites, By such a mechanism, an anti-cancer drug having excellent anti-cancer effectiveness may be screened, or the effectiveness of the anti-cancer drug may be tested.
    Type: Application
    Filed: February 1, 2011
    Publication date: August 4, 2011
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Kang-Yell CHOI, Woo-Jeong JEONG
  • Publication number: 20110135652
    Abstract: There are provided Idbf (inhibitor of Dvl and Bone formation) which is a novel Dvl-binding protein that binds to Dvl to inhibit signal transduction carried out through the Wnt/?-catenin signaling pathway, a gene for coding for the same, the use thereof, and the use of an inhibitor of the Idbf. The Idbf was known to be expressed by activation of the Wnt/?-catenin signaling pathway and bind to Dvl to block signal transduction carried out through the Wnt/?-catenin signaling pathway. Therefore, the Idbf can be used in development of medicines for inhibiting the signal transduction carried out through the Wnt/?-catenin signaling pathway, and an Idbf inhibitor can be used in preparation of medicines for activating the signal transduction carried out through the Wnt/?-catenin signaling pathway.
    Type: Application
    Filed: August 3, 2009
    Publication date: June 9, 2011
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITY
    Inventors: Kang-Yell Choi, Hyun-Yi Kim, Ju-Yong Yoon